Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Cytek BioSciences Inc’s stock clocked out at $5.05, down -0.98% from its previous closing price of $5.1. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 0.53 million shares were traded. CTKB stock price reached its highest trading level at $5.09 during the session, while it also had its lowest trading level at $4.95.
Ratios:
To gain a deeper understanding of CTKB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 5.17. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 09, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $4.
Goldman Downgraded its Buy to Sell on January 31, 2025, whereas the target price for the stock was revised from $7 to $4.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 645717440 and an Enterprise Value of 408809376. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.28 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 2.077 whereas that against EBITDA is -15.216.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.29, which has changed by -0.21417564 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.30, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 5.08%, while the 200-Day Moving Average is calculated to be 28.87%.
Shares Statistics:
It appears that CTKB traded 1.24M shares on average per day over the past three months and 1254450 shares per day over the past ten days. A total of 127.86M shares are outstanding, with a floating share count of 115.96M. Insiders hold about 9.31% of the company’s shares, while institutions hold 62.79% stake in the company. Shares short for CTKB as of 1765756800 were 6790609 with a Short Ratio of 5.48, compared to 1763078400 on 6639767. Therefore, it implies a Short% of Shares Outstanding of 6790609 and a Short% of Float of 6.9.
Earnings Estimates
. The current rating of Cytek BioSciences Inc (CTKB) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.04 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is -$0.01, with 2.0 analysts recommending between -$0.01 and -$0.02.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $57.09M. It ranges from a high estimate of $58.76M to a low estimate of $55.4M. As of. The current estimate, Cytek BioSciences Inc’s year-ago sales were $57.48MFor the next quarter, 4 analysts are estimating revenue of $44.1M. There is a high estimate of $44.9M for the next quarter, whereas the lowest estimate is $42.62M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $198.11M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $196.71M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $207.45M in the next fiscal year. The high estimate is $211.82M and the low estimate is $203.3M.
